NCT07112651View on ClinicalTrials.gov

Efficacy of CL25216 on Vasomotor Symptoms in Women During Perimenopause

NANot yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 20, 2025

Primary Completion Date

April 29, 2026

Study Completion Date

April 29, 2026

Conditions
Vasomotor Symptoms
Interventions
DIETARY_SUPPLEMENT

CL25216

250mg to take one capsule a day after breakfast for 105 days

DIETARY_SUPPLEMENT

Placebo

One capsule a day after breakfast for 105 days

All Listed Sponsors
lead

ApexCPG LLC

INDUSTRY

NCT07112651 - Efficacy of CL25216 on Vasomotor Symptoms in Women During Perimenopause | Biotech Hunter | Biotech Hunter